Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Gastrointestinal stromal tumour (GIST), drawn from the whole corpus: 13 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Polyclonal resistance: different lesions carry different secondary KIT mutations.
Nothing recorded yet.
Background: Circulating tumour DNA (ctDNA), Drug resistance (primary and acquired). Also on OnCo: Resistance atlas · Lines of therapy.
SDH-deficient and other wild-type GIST have no effective TKI.
Optimal duration of adjuvant imatinib (3 vs 5-6 years).
Long-term imatinib toxicity and adherence.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Side effects by symptom · Immune-related side effects · Toxicity compare · Survivorship planner.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 19 changes by month →When this page itself was last checked or edited.
A milestone in how this cancer is treated.
Unresectable/metastatic GIST with PDGFRA exon 18 mutation including D842V
Advanced GIST after ≥3 prior kinase inhibitors including imatinib
Very high, durable response rate in PDGFRA D842V-mutant GIST; approved for that indication in January 2020.
A milestone in how this cancer is treated.